Kura Oncology Surges with COMZIFTI | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20070415

Show notes

Kura Oncology is on fire, with COMZIFTI raking in $9.1M in just its second quarter on the market—surpassing expectations and dominating new patient starts in relapsed/refractory NPM1-mutant AML. Doctors are clearly seeing something special in its profile. Beyond launch, Kura’s pushing COMZIFTI into frontline AML combos, with early data showing deeper responses and longer-lasting results. Darlifarnib, meanwhile, is emerging as a standalone powerhouse, boosting targeted therapies for kidney cancer and KRAS G12C tumors with manageable side effects. With strong commercial footing, a growing pipeline, and over $519M in cash to fund key trials through 2028, Kura’s multi-pronged strategy is setting them up for explosive growth across oncology. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/207582d54dde139d

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.